Sign in

    IDEXX Laboratories Inc (IDXX)

    You might also like

    IDEXX Laboratories, Inc. is a company engaged in the development, manufacturing, and distribution of products and services for various sectors, including companion animal veterinary, livestock, poultry and dairy, water testing, and human medical diagnostics . The company operates through three main business segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD) . IDEXX's business model is heavily reliant on a recurring revenue structure, supported by strong customer loyalty and high retention rates .

    1. Companion Animal Group (CAG) - Provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, reference laboratory services, and veterinary software.
    2. Water - Develops products used to detect microbiological parameters in water.
    3. Livestock, Poultry and Dairy (LPD) - Offers diagnostic tests and services to manage livestock and poultry health and ensure milk quality and safety.
    4. OPTI Medical - Focuses on human medical diagnostics.
    NamePositionExternal RolesShort Bio

    Andrew Emerson

    Executive

    EVP, CFO, and Treasurer (effective March 1, 2025)

    None

    Joined IDEXX in 2015. Previously led CAG Finance and corporate finance functions. Assumes CFO role on March 1, 2025.

    Brian P. McKeon

    Executive

    EVP, CFO, and Treasurer (until March 1, 2025)

    Director at Alkermes plc

    Joined IDEXX in January 2014. Leads finance and investor relations. Announced retirement effective June 1, 2025, with transition to Andrew Emerson.

    George J. Fennell

    Executive

    SVP, Chief Revenue Officer

    None

    Joined IDEXX in 2011. Leads global commercial sales and field support teams.

    Jonathan J. Mazelsky

    Executive

    President and CEO

    Board Member at Dentsply Sirona Inc.

    Joined IDEXX in 2012; became CEO in October 2019. Focuses on innovation and sustainable growth. Previously EVP at IDEXX and led multiple business lines.

    View Report →

    Michael Erickson, PhD

    Executive

    EVP, Global Point of Care Diagnostics and Telemedicine

    None

    Joined IDEXX in 2011. Held multiple leadership roles, including SVP and GM of Veterinary Software and Services.

    Michael J. Lane

    Executive

    EVP, Global Reference Laboratories and IT

    None

    Joined IDEXX in 1997. Played a key role in strategic planning for the global reference laboratory market.

    Michael P. Johnson

    Executive

    EVP, Chief Human Resources Officer

    None

    Joined IDEXX in March 2022. Previously held senior HR roles at Abbott Laboratories.

    Sharon E. Underberg

    Executive

    EVP, General Counsel, and Corporate Secretary

    None

    Joined IDEXX in February 2019. Leads global legal, governance, and compliance functions. Previously General Counsel at Eastman Kodak.

    Bruce L. Claflin

    Board

    Independent Director

    Director at Ciena Corporation

    Joined IDEXX Board in 2015. Former CEO of 3Com Corporation and Non-Executive Chair at AMD.

    Daniel M. Junius

    Board

    Independent Director

    Director at GlycoMimetics, Inc.

    Joined IDEXX Board in 2014. Former CEO of ImmunoGen, Inc..

    Irene Chang Britt

    Board

    Independent Director

    Director at First Watch Restaurant Group, Inc.; Director at Victoria’s Secret & Co.

    Joined IDEXX Board in 2023. Former President of Pepperidge Farm and senior executive at Campbell Soup Company.

    Lawrence D. Kingsley

    Board

    Independent Non-Executive Board Chair

    Non-Executive Chair at Mirion Technologies, Inc.; Director at Polaris Industries Inc.; Advisory Director at Berkshire Partners LLC

    Joined IDEXX Board in 2016. Former CEO of Pall Corporation and IDEX Corporation.

    M. Anne Szostak

    Board

    Independent Director

    Founder and President of Szostak Partners; Director at Tupperware Brands Corporation

    Joined IDEXX Board in 2012. Extensive experience in human resources and governance.

    Sam Samad

    Board

    Independent Director

    EVP and CFO at Quest Diagnostics Incorporated

    Joined IDEXX Board in 2019. Former CFO at Illumina, Inc..

    Program DetailsProgram 1
    Approval DateAugust 13, 1999
    End Date/DurationNo specified expiration date
    Total additional amountN/A
    Remaining authorization amount1,696,986 shares as of September 30, 2024
    DetailsThe program is intended to return value to stockholders and offset the dilutive effect of share-based compensation programs. Shares are acquired through open market repurchases and employee share surrenders for tax withholding.
    YearAmount Due (Millions)Debt TypeInterest Rate (%)% of Total Debt
    2025$75.02025 Series B Notes4.048.6% = (75 / 873.9) * 100
    2025$99.12025 Series C Notes1.78511.3% = (99.1 / 873.9) * 100
    2026$75.02026 Senior Notes3.728.6% = (75 / 873.9) * 100
    2027$75.02027 Series B Notes3.728.6% = (75 / 873.9) * 100
    2029$100.02029 Series C Notes4.1911.4% = (100 / 873.9) * 100
    2030$125.0MetLife 2030 Series D Notes2.5014.3% = (125 / 873.9) * 100
    2030$75.0Prudential 2030 Series D Notes2.508.6% = (75 / 873.9) * 100

    Competitors mentioned in the company's latest 10K filing.

    CompanyDescription

    Mars, Incorporated

    The company competes primarily on the basis of ease of use and speed of products, diagnostic accuracy, product quality, and other factors. In North America, the major competitors include brands such as Antech Diagnostics and Heska. In certain international geographies, the competition includes brands like Heska, Antech Diagnostics, Scil, and Asia Veterinary Diagnostics.

    The company competes with this entity in most geographic locations in North America and in certain international geographies.

    The company competes with this entity in certain international geographies.

    Samsung Electronics

    The company competes with this entity in certain international geographies.

    Arkray, Inc.

    The company competes with this entity in certain international geographies.

    Mindray

    The company competes with this entity in certain international geographies.

    BioNote, Inc.

    The company competes with this entity in certain international geographies.

    Covetrus, Inc.

    The largest competitor in North America and the U.K. in the veterinary software, services, and diagnostic imaging systems sector. This competitor offers several systems and leverages its animal health distribution business in sales and service.

    Sound-Eklin

    A competitor in the diagnostic imaging systems sector.

    Radiometer A/S

    A competitor in the human point-of-care medical diagnostic products sector.

    Siemens Medical Solutions Diagnostics

    A competitor in the human point-of-care medical diagnostic products sector.

    Instrumentation Laboratory Company

    A competitor in the human point-of-care medical diagnostic products sector.

    A division of Abbott Laboratories, competing in the human point-of-care medical diagnostic products sector.

    Roche Diagnostics Corporation

    A competitor in the human point-of-care medical diagnostic products sector.

    VCA Inc.

    A corporate hospital chain that operates reference laboratories serving both their hospitals and unaffiliated hospitals, wholly owned by Mars, Incorporated.

    NameStart DateEnd DateReason for Change
    PricewaterhouseCoopers LLP2002 PresentCurrent auditor

    Notable M&A activity and strategic investments in the past 3 years.

    CompanyYearDetails

    U.S. privately-owned software and data platform

    2024

    Deal value: Approximately $77 million in cash with up to $30 million in contingent payments; structure: Detailed purchase price allocation for technology, customer relationships, non-compete, trademark, goodwill, and net tangible assets. Strategic rationale: Enhances IDEXX’s cloud-native practice management workflow and expands its strategic data solutions within the Companion Animal Group.

    GreenLine Pet

    2024

    Deal details: Completed in Q1 2024, this acquisition strengthens IDEXX’s portfolio with a leading digital platform for practice workflow solutions focused on coupon and rebate redemptions. Strategic rationale: It supports enhanced partnerships with major manufacturers in animal health and drives integrated vertical SaaS adoption in IDEXX’s cloud practice management systems.

    International water testing company (Canada)

    2022

    Deal value: Approximately $12.8 million in cash (including a $1.3 million holdback) with purchase price allocation across technology intangibles, customer relationship intangibles, tangible assets, and goodwill. Strategic rationale: The acquisition is aimed at broadening the Water segment’s product portfolio by leveraging synergies from the water testing business.

    No recent press releases or 8-K filings found for IDXX.